EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Case Report: Adebrelimab-associated suspected immune-related myocarditis with myositis/myasthenia gravis overlap syndrome (IM3OS): A rapidly fatal case and clinical implications

Hongyan Ji, Haijun Qu, Donghua Liu, Wen Xu, Xinyi Wang, Mengna Cui, Qie Guo, Fanbo Jin, Yuanxin Miao

Frontiers in Oncology · 19.06.2026 · 16

DOI: 10.3389/fonc.2026.1778682 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Frontiers in Oncology, online erschienen am 19.06.2026. Verfasst von Hongyan Ji und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This article reports a case of a 72-year-old male with intrahepatic cholangiocarcinoma who developed acute symptoms—including chest tightness, muscle weakness, ophthalmoplegia, and dyspnea—3 days after receiving the second cycle of adebrelimab, following combination therapy with adebrelimab, apatinib, and tegafur. These complications proved fatal. Laboratory tests showed significant elevation of myocardial injury markers (high-sensitivity troponin T, N-terminal pro-B-type natriuretic peptide, myoglobin, and creatine kinase). Electrocardiogram showed multi-lead ST-T changes and conduction abnormalities, and neurological examination showed ophthalmoplegia. Immune checkpoint inhibitor-associated myocarditis with myositis/myasthenia gravis overlap syndrome (IM3OS) was highly suspected. Despite immediate drug discontinuation and progressive immunosuppression with corticosteroids and intravenous immune globulin, the patient’s condition worsened, and cardiac arrest occurred on day 9. This case underscores the rapid onset and poor prognosis associated with adebrelimab-induced suspected IM3OS, highlighting the critical need for rigorous baseline assessment, prompt recognition, early initiation of aggressive immunosuppressive therapy, and coordinated multidisciplinary management to prevent or mitigate these potentially life-threatening immune-related adverse events.

Schlagwörter

Stichwörter der Autor:innen

IM3OSadebrelimabimmune checkpoint inhibitorsimmune-related adverse eventsmyasthenia gravismyocarditis

Autor:innen und Institutionen

  • Department of Pharmacy, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
  • Department of Plastic Surgery, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.

Zitieren

APA

Ji, H., Qu, H., Liu, D., Xu, W., Wang, X., Cui, M., Guo, Q., Jin, F., & Miao, Y. (2026). Case Report: Adebrelimab-associated suspected immune-related myocarditis with myositis/myasthenia gravis overlap syndrome (IM3OS): A rapidly fatal case and clinical implications. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1778682

Vancouver

Ji H, Qu H, Liu D, Xu W, Wang X, Cui M, et al. Case Report: Adebrelimab-associated suspected immune-related myocarditis with myositis/myasthenia gravis overlap syndrome (IM3OS): A rapidly fatal case and clinical implications. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1778682

BibTeX
@article{Ji2026,
  author = {Ji, Hongyan and Qu, Haijun and Liu, Donghua and Xu, Wen and Wang, Xinyi and Cui, Mengna and Guo, Qie and Jin, Fanbo and Miao, Yuanxin},
  title = {Case Report: Adebrelimab-associated suspected immune-related myocarditis with myositis/myasthenia gravis overlap syndrome (IM3OS): A rapidly fatal case and clinical implications},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1778682}
}
Kostenlos starten →